Vantage Financial Partners Ltd. Inc. trimmed its holdings in Biogen Inc (NASDAQ:BIIB) by 13.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,000 shares of the biotechnology company’s stock after selling 304 shares during the period. Vantage Financial Partners Ltd. Inc.’s holdings in Biogen were worth $638,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also added to or reduced their stakes in the company. Comgest Global Investors S.A.S. boosted its position in Biogen by 5.9% during the fourth quarter. Comgest Global Investors S.A.S. now owns 18,000 shares of the biotechnology company’s stock worth $5,734,000 after purchasing an additional 1,000 shares during the period. Timber Hill LLC bought a new position in shares of Biogen in the fourth quarter valued at approximately $1,549,000. Baird Financial Group Inc. boosted its position in shares of Biogen by 2.8% in the fourth quarter. Baird Financial Group Inc. now owns 143,027 shares of the biotechnology company’s stock valued at $45,564,000 after acquiring an additional 3,954 shares during the period. Norinchukin Bank The boosted its position in shares of Biogen by 4.4% in the fourth quarter. Norinchukin Bank The now owns 27,623 shares of the biotechnology company’s stock valued at $8,800,000 after acquiring an additional 1,153 shares during the period. Finally, Ontario Teachers Pension Plan Board lifted its position in Biogen by 27.8% during the fourth quarter. Ontario Teachers Pension Plan Board now owns 8,185 shares of the biotechnology company’s stock valued at $2,607,000 after purchasing an additional 1,778 shares during the last quarter. 88.96% of the stock is currently owned by hedge funds and other institutional investors.
BIIB has been the subject of several research analyst reports. Piper Jaffray Companies reiterated a “buy” rating and set a $390.00 target price on shares of Biogen in a research report on Monday, December 18th. Nomura lifted their target price on shares of Biogen from $355.00 to $420.00 and gave the stock a “buy” rating in a research note on Friday, December 22nd. Royal Bank of Canada reaffirmed a “hold” rating and issued a $321.00 target price on shares of Biogen in a research note on Tuesday, December 5th. Credit Suisse Group raised shares of Biogen from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $321.00 to $385.00 in a research report on Wednesday, December 20th. Finally, Mizuho set a $400.00 target price on shares of Biogen and gave the company a “buy” rating in a report on Thursday, January 18th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and twenty-two have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $370.07.
Biogen Inc (NASDAQ:BIIB) traded up $2.48 on Wednesday, reaching $285.72. The company’s stock had a trading volume of 2,026,366 shares, compared to its average volume of 1,840,000. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.34 and a quick ratio of 2.07. The stock has a market capitalization of $60,450.00, a price-to-earnings ratio of 16.36, a PEG ratio of 1.54 and a beta of 0.91. Biogen Inc has a 52 week low of $244.28 and a 52 week high of $370.57.
Biogen (NASDAQ:BIIB) last released its earnings results on Thursday, January 25th. The biotechnology company reported $5.26 EPS for the quarter, missing the Zacks’ consensus estimate of $5.44 by ($0.18). Biogen had a return on equity of 38.32% and a net margin of 20.69%. The firm had revenue of $3.31 billion for the quarter, compared to analyst estimates of $3.08 billion. During the same period last year, the firm earned $5.04 EPS. The company’s revenue for the quarter was up 15.1% compared to the same quarter last year. research analysts predict that Biogen Inc will post 24.87 earnings per share for the current fiscal year.
Biogen Company Profile
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.